secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-331244
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio expands ATM equity offering capacity by $460M; authorized shares increased by 300M
--------------------------------------------------------------------------------

- Amendment to ATM agreement with Jefferies LLC authorizes up to $459.97M in additional common stock sales.
- Board and stockholders approved increase in authorized common shares from 1.35B to 1.65B, effective Nov 10, 2025.
- ATM sales will be made under existing S-3ASR shelf registration and prospectus supplement dated Dec 23, 2025.
- Amendment also updates settlement to T+1 and modifies auditor comfort letter delivery requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/0001193125-25-331244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-331244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer